Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities.

Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities.
复制标题

淀粉样蛋白和神经退行性血浆生物标志物与合并症的关联。

DOI:
10.1002/alz.12466
复制
发表时间:
2022-06
期刊:
Alzheimer's & dementia : the journal of the Alzheimer's Association
影响因子:
--
通讯作者:
Mielke MM
Mielke MM
中科院分区:
其他
文献类型:
--
作者:
Syrjanen JA;Campbell MR;Algeciras-Schimnich A;Vemuri P;Graff-Radford J;Machulda MM;Bu G;Knopman DS;Jack CR Jr;Petersen RC;Mielke MM

文献摘要

参考文献

被引文献

相似文献

淀粉样蛋白病理学和神经变性的基于血液的生物标志物正在进入临床使用。了解哪些因素影响这些标记物的水平至关重要。在Quanterix Simoa® HD-1分析仪上测量了996名年龄在51 - 95岁之间的马约临床衰老研究(MCSA)参与者的血浆标志物(Aβ42、Aβ40、NfL、T-tau、Aβ42/40)。所有其他数据均在MCSA访视期间收集或从病历中提取。在认知未受损(CU)中,所有血浆标志物均与年龄相关。线性回归模型揭示了多重关系。例如,较高的Charlson合并症指数和慢性肾脏疾病与所有生物标志物的较高水平相关。轻度认知障碍和痴呆症参与者之间的一些关系有所不同。多个变量影响普通人群中CU中淀粉样蛋白病理学和神经变性的血浆生物标志物。阐明这些信息对于准确解释生物标志物水平和制定参考范围至关重要。
Blood-based biomarkers of amyloid pathology and neurodegeneration are entering clinical use. It is critical to understand what factors affect the levels of these markers. Plasma markers (Aβ42, Aβ40, NfL, T-tau, Aβ42/40) were measured on the Quanterix Simoa® HD-1 analyzer for 996 Mayo Clinic Study of Aging (MCSA) participants, aged 51 to 95 years. All other data were collected during in-person MCSA visits or abstracted from the medical record. Among cognitively unimpaired (CU), all plasma markers correlated with age. Linear regression models revealed multiple relationships. For example, higher Charlson comorbidity index and chronic kidney disease were associated with higher levels of all biomarkers. Some relationships differed among MCI and dementia participants. Multiple variables affect plasma biomarkers of amyloid pathology and neurodegeneration among CU in the general population. Incorporating this information is critical for accurate interpretation of the biomarker levels and for the development of reference ranges.
DOI: 10.1212/wnl.0000000000003246
发表时间: 2016-10-25
期刊: Neurology
影响因子: 9.9
作者:
Mattsson N;Zetterberg H;Janelidze S;Insel PS;Andreasson U;Stomrud E;Palmqvist S;Baker D;Tan Hehir CA;Jeromin A;Hanlon D;Song L;Shaw LM;Trojanowski JQ;Weiner MW;Hansson O;Blennow K;ADNI Investigators
通讯作者: ADNI Investigators
DOI: 10.3233/jad-180582
发表时间: 2018
期刊: Journal of Alzheimer's disease : JAD
影响因子: --
作者:
Baghallab I;Reyes-Ruiz JM;Abulnaja K;Huwait E;Glabe C
通讯作者: Glabe C
DOI: 10.1001/jamaneurol.2016.6117
发表时间: 2017-05-01
期刊: JAMA neurology
影响因子: 29
作者:
Mattsson N;Andreasson U;Zetterberg H;Blennow K;Alzheimer’s Disease Neuroimaging Initiative
通讯作者: Alzheimer’s Disease Neuroimaging Initiative
DOI: 10.1093/brain/awaa286
发表时间: 2020-12-05
期刊: Brain : a journal of neurology
影响因子: --
作者:
Mattsson-Carlgren N;Janelidze S;Palmqvist S;Cullen N;Svenningsson AL;Strandberg O;Mengel D;Walsh DM;Stomrud E;Dage JL;Hansson O
通讯作者: Hansson O
DOI: 10.1186/s13195-018-0404-9
发表时间: 2018-07-28
期刊: Alzheimer's research & therapy
影响因子: --
作者:
Lewczuk P;Ermann N;Andreasson U;Schultheis C;Podhorna J;Spitzer P;Maler JM;Kornhuber J;Blennow K;Zetterberg H
通讯作者: Zetterberg H